New Immunotherapy Combinations: A Practical Oncology Update for 2025

Recent Trends in Combination Strategies

Over the past 18 to 24 months, the oncology field has seen a marked shift from single-agent immunotherapy toward rationally designed combination regimens. These pairings fall into several categories:

• Dual checkpoint inhibition — combining PD-1/PD-L1 blockers with CTLA-4 or LAG-3 inhibitors to target complementary immune escape pathways.
• Immunotherapy plus targeted therapy — for example, combining checkpoint inhibitors with tyrosine kinase inhibitors or PARP inhibitors in molecularly defined subsets.
• Bispecific antibodies and cell engagers — newer constructs that bridge immune cells directly to tumor antigens, sometimes co-administered with checkpoint blockers to deepen response.
• Immunotherapy with antibody-drug conjugates (ADCs) — leveraging the cytotoxic payload of ADCs to create immunogenic cell death and prime the immune system.

These strategies are being evaluated across multiple tumor types, with lung cancer, melanoma, renal cell carcinoma, and gastrointestinal malignancies leading the pipeline.

Background: Why Combinations Are Gaining Traction

Single-agent PD-1/PD-L1 inhibitors, while transformative for a subset of patients, leave many with primary or acquired resistance. The immunological rationale for combining agents is well established: blocking multiple checkpoints, engaging innate immunity, or targeting the tumor microenvironment can overcome escape mechanisms. Early successes — for instance, dual checkpoint regimens in melanoma and PD-1 plus chemotherapy in non-small cell lung cancer — set a precedent. Current development builds on this by incorporating newer targets such as TIGIT, VISTA, or specific costimulatory agonists.

Real-world evidence and meta-analyses continue to show that the magnitude of benefit from combination therapy depends heavily on tumor type, biomarker status (e.g., PD-L1 expression, tumor mutational burden, microsatellite instability), and prior treatment history. No single combination works across all contexts.

Key Considerations for Clinicians and Patients

When evaluating new immunotherapy combinations for 2025, several practical factors warrant attention:

• Toxicity profiles — dual checkpoint regimens, in particular, carry higher rates of immune-related adverse events (irAEs), including colitis, pneumonitis, and endocrinopathies. Management pathways must be established early.
• Biomarker selection — many ongoing trials require PD-L1 expression thresholds or tumor mutational burden cutoffs. Off-label use without appropriate testing may yield lower response rates and increased toxicity.
• Sequencing and treatment duration — it is not yet clear how long to continue combination therapy after best response, or whether maintenance monotherapy is preferable. Some protocols cap combination cycles and switch to single-agent.
• Cost and access — combination regimens often increase drug costs, infusion time, and monitoring requirements. Formulary decisions and prior authorization criteria vary across institutions and payers.
• Patient performance status — patients with ECOG scores ≥2 may not tolerate the added toxicity of combination therapy; careful patient selection remains critical.

“The challenge is not just generating more trials but translating the right combination to the right patient at the right time,” noted in recent clinical practice discussions.

Likely Impact on Standard Treatment Pathways

If current late-stage trials report positive results, several changes to standard pathways could occur:

• First-line shifts — combinations may supplant single-agent immunotherapy in tumors where benefit is marginal with monotherapy (e.g., certain PD-L1 low groups).
• Adjuvant and neoadjuvant settings — earlier introduction of immunotherapy with targeted agents might improve pathologic complete response rates and reduce relapse risk.
• Biomarker-driven approvals — regulators are increasingly requiring companion diagnostics; treatment pathways will likely become more stratified.
• Monitoring protocols — routine imaging and lab schedules may need adjustment to detect early irAEs or pseudoprogression.

However, not all promising phase II combinations succeed in phase III. Tolerability and improvement in overall survival, rather than just progression-free survival, will determine real-world adoption.

What to Watch Next

As 2025 progresses, several developments deserve close attention:

• Phase III readouts — results from ongoing registrational trials evaluating PD-1/TIGIT combinations in lung cancer and PD-1/LAG-3 regimens in melanoma are expected within the next 6 to 12 months.
• Regulatory decisions — FDA and EMA decisions on bispecific antibody–checkpoint inhibitor combos in multiple myeloma and CD20-targeted bispecifics in lymphoma.
• Biomarker refinement — efforts to integrate composite biomarkers (e.g., combined gene signatures plus PD-L1) into routine testing algorithms.
• Real-world evidence — forthcoming registry studies and post-marketing analyses will clarify whether combination benefits observed in trials translate into routine practice.
• Cost-effectiveness analyses — health technology assessments may influence coverage decisions and shape which combinations become accessible.

Ultimately, the pace of clinical implementation will depend on clear data showing a meaningful survival advantage without unmanageable toxicity, as well as the readiness of healthcare systems to support biomarker-guided therapy selection.